Related Experiment Videos
[Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases]
Insights
Neoplastic diseases, including lung cancer, show elevated serum complement components and immune complexes, correlating with advanced disease stages. These immune markers may indicate disease progression in cancer patients.
Area of Science:
- Immunology
- Oncology
Context:
- Investigating immune system alterations in patients with neoplastic diseases.
- Understanding the role of complement system and immune complexes in cancer pathology.
Purpose:
- To measure serum levels of complement components (cc), whole complement activity (CH 50), and circulating immune complexes (IC) in patients with neoplastic diseases.
- To explore correlations between these immune markers and clinical parameters, specifically in lung cancer patients.
Summary:
- Patients with neoplastic diseases exhibited higher serum levels of complement components (cc) compared to healthy controls, with specific elevations in C1q, C1INA, C4, C3c, C3ACT, C5, and C9.
- In lung cancer patients, elevated cc levels correlated with clinical stage and performance status. Higher immune complex (IC) serum levels and incidence were observed in Stages III and IV compared to Stages I and II.
- Serum CH 50 levels were higher in patients than controls but did not correlate with clinical stage.
Impact:
- Provides insights into immune dysregulation in neoplastic diseases.
- Suggests potential utility of complement components and immune complexes as biomarkers for cancer progression and staging, particularly in lung cancer.
- Highlights differences in immune complex profiles based on cancer stage.
Abstract:
Serum levels of complement components(cc), whole complement activity (CH 50), and circulating immune complexes (IC) were measured in 41 patients with neoplastic diseases. The level of cc was higher than in healthy controls; the levels of C1q, C1INA, C4, C3c, C3ACT, C5, and C9 were statistically higher. In patients with lung cancer, the levels of cc were correlated with the clinical stage as well as the performance status. Both the IC serum level and the incidence of high serum IC levels in lung cancer were higher in stage III and IV than in stage I and II. Serum CH 50 was higher than in healthy controls, but not correlated with the clinical stage.